ArticleClinical diabetes : a publication of the American Diabetes Association2016

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.

Charles F ShaeferPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.